MK-0524A Approval Status 
- FDA approved: No
- Brand name: MK-0524A
- Generic name: niacin ER and laropiprant
- Previous name: Cordaptive
- Company: Merck & Co., Inc.
- Treatment for: Hyperlipoproteinemia Type IIa, Elevated LDL, Hypertriglyceridemia
MK-0524A is an investigational compound containing extended-release niacin and laropiprant, a novel flushing pathway inhibitor designed to reduce flushing often associated with niacin treatment. MK-0524A is used either alone or with a statin, as adjunctive therapy to diet for the treatment of elevated LDL cholesterol, low HDL cholesterol and elevated triglyceride levels.
FDA Approval Status for MK-0524A
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
